<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39599909</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Beyond Antivirals: Alternative Therapies for Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1795</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16111795</ELocationID><Abstract><AbstractText>Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) is a condition characterized by numerous lingering symptoms that persist for weeks to months following the viral illness. While treatment for PASC is still evolving, several therapeutic approaches beyond traditional antiviral therapies are being investigated, such as immune-modulating agents, anti-inflammatory drugs, and various supportive interventions focusing at alleviating symptoms and enhancing recovery. We aimed to summarize the breadth of available evidence, identify knowledge gaps, and highlight promising non-antiviral therapies for Long COVID/PASC. We followed the framework of a scoping methodology by mapping existing evidence from a range of studies, including randomized clinical trials, observational research, and case series. Treatments evaluated include metformin, low-dose naltrexone (LDN), dexamethasone, statins, omega-3 fatty acids, L-arginine, and emerging therapies like intravenous immunoglobulin (IVIg) and therapeutic apheresis. Early findings suggest that metformin has the strongest clinical evidence, particularly from large phase 3 trials, while LDN and dexamethasone show potential based on observational studies. However, many treatments lack robust, large-scale trials. This review emphasizes the need for further research to confirm the efficacy of these treatments and guide clinical practice for Long COVID management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Livieratos</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Independent Researcher, 15238 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gogos</LastName><ForeName>Charalambos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Patras, 26504 Rio, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinosoglou</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4289-9494</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Patras, 26504 Rio, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">non-antiviral treatments</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39599909</ArticleId><ArticleId IdType="doi">10.3390/v16111795</ArticleId><ArticleId IdType="pii">v16111795</ArticleId><ArticleId IdType="pmc">PMC11599064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ely E.W., Brown L.M., Fineberg H.V. Long Covid Defined. N. Engl. J. Med. 2024;391:1746&#x2013;1753. doi: 10.1056/NEJMsb2408466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2408466</ArticleId><ArticleId IdType="pubmed">39083764</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A., Lowe N., Arnsten A.F.T. Clinical Experience with the &#x3b1;2A-adrenoceptor Agonist, Guanfacine, and N-acetylcysteine for the Treatment of Cognitive Deficits in &#x201c;Long-COVID19&#x201d;. Neuroimmunol. Rep. 2023;3:100154. doi: 10.1016/j.nerep.2022.100154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nerep.2022.100154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen K.S., Mogensen T.H., Agergaard J., Schi&#xf8;ttz-Christensen B., &#xd8;stergaard L., Vibholm L.K., Leth S. High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial. Lancet Reg. Health Eur. 2023;24:100539. doi: 10.1016/j.lanepe.2022.100539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100539</ArticleId><ArticleId IdType="pmc">PMC9627534</ArticleId><ArticleId IdType="pubmed">36337437</ArticleId></ArticleIdList></Reference><Reference><Citation>Livieratos A., Gogos C., Akinosoglou K. SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature. Viruses. 2024;16:1222. doi: 10.3390/v16081222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16081222</ArticleId><ArticleId IdType="pmc">PMC11359867</ArticleId><ArticleId IdType="pubmed">39205196</ArticleId></ArticleIdList></Reference><Reference><Citation>Livieratos A., Gogos C., Akinosoglou K. Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes. Viruses. 2024;16:685. doi: 10.3390/v16050685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16050685</ArticleId><ArticleId IdType="pmc">PMC11125779</ArticleId><ArticleId IdType="pubmed">38793566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz T.K., Brondstater K.N. Long COVID management: A mini review of current recommendations and underutilized modalities. Front. Med. 2024;11:1430444. doi: 10.3389/fmed.2024.1430444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1430444</ArticleId><ArticleId IdType="pmc">PMC11211541</ArticleId><ArticleId IdType="pubmed">38947233</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., Dhodapkar R.M., Lu P., Gehlhausen J.R., Tabachnikova A., Greene K., Tabacof L., Malik A.A., et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139&#x2013;148. doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2022;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntur V.P., Nemkov T., de Boer E., Mohning M.P., Baraghoshi D., Cendali F.I., San-Mill&#xe1;n I., Petrache I., D&#x2019;Alessandro A. Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC) Metabolites. 2022;12:1026. doi: 10.3390/metabo12111026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12111026</ArticleId><ArticleId IdType="pmc">PMC9699059</ArticleId><ArticleId IdType="pubmed">36355108</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Resendiz K.J.G., Benitez-Trinidad A.B., Covantes-Rosales C.E., Toledo-Ibarra G.A., Ortiz-Lazareno P.C., Gir&#xf3;n-P&#xe9;rez D.A., Bueno-Dur&#xe1;n A.Y., P&#xe9;rez-D&#xed;az D.A., Barcelos-Garc&#xed;a R.G., Gir&#xf3;n-P&#xe9;rez M.I. Loss of mitochondrial membrane potential (&#x394;&#x3a8;(m)) in leucocytes as post-COVID-19 sequelae. J. Leukoc. Biol. 2022;112:23&#x2013;29. doi: 10.1002/JLB.3MA0322-279RRR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3MA0322-279RRR</ArticleId><ArticleId IdType="pmc">PMC9088601</ArticleId><ArticleId IdType="pubmed">35355308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi A. COVID-19 and Mitochondrial Non-Coding RNAs: New Insights From Published Data. Front. Physiol. 2021;12:805005. doi: 10.3389/fphys.2021.805005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.805005</ArticleId><ArticleId IdType="pmc">PMC8856670</ArticleId><ArticleId IdType="pubmed">35185603</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl. Acad. Sci. USA. 2021;118:e2024358118. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S., Kril I., Nadizhko O., Matsyura O., Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: A pilot observational study. Rheumatol. Int. 2022;42:1523&#x2013;1530. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., Ibn Hadj Amor H., Jdidi J., Torjmen S., Kraiem S., Hammami R., Bahloul A., Kallel N., Moussa N., Touil I., et al. Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights from TUN-EndCOV Study. Front. Cardiovasc. Med. 2021;8:745758. doi: 10.3389/fcvm.2021.745758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., F&#xfc;rst J., Schulze-Rothe S., Wallukat A., H&#xf6;nicke A.S., M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Mu&#xf1;oz P., Aldamiz T., Diez C., Perez L., Fanciulli C., et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis. 2022;22:211. doi: 10.1186/s12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceulemans L.J., Khan M., Yoo S.J., Zapiec B., Van Gerven L., Van Slambrouck J., Vanstapel A., Van Raemdonck D., Vos R., Wauters E., et al. Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir. Med. 2021;9:e78&#x2013;e79. doi: 10.1016/S2213-2600(21)00240-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00240-X</ArticleId><ArticleId IdType="pmc">PMC8189667</ArticleId><ArticleId IdType="pubmed">34118186</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen N.W., Stiles L.E., Shaik R., Schneider L., Muppidi S., Tsui C.T., Geng L.N., Bonilla H., Miglis M.G. Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults. Front. Neurol. 2022;13:1012668. doi: 10.3389/fneur.2022.1012668.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.1012668</ArticleId><ArticleId IdType="pmc">PMC9639503</ArticleId><ArticleId IdType="pubmed">36353127</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.J., Bin Seo Y., Seo J.W., Lee J., Nham E., Seong H., Yoon J.G., Noh J.Y., Cheong H.J., Kim W.J., et al. Effectiveness of Antiviral Therapy on Long COVID: A Systematic Review and Meta-Analysis. J. Clin. Med. 2023;12:7375. doi: 10.3390/jcm12237375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12237375</ArticleId><ArticleId IdType="pmc">PMC10707593</ArticleId><ArticleId IdType="pubmed">38068427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L., Abarikwu S.O., Arero A.G., Essouma M., Jibril A.T., Fal A., Flisiak R., Makuku R., Marquez L., Mohamed K., et al. Oral antiviral treatments for COVID-19: Opportunities and challenges. Pharmacol. Rep. 2022;74:1255&#x2013;1278. doi: 10.1007/s43440-022-00388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pmc">PMC9309032</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta M.A., Marino G., Spagnolo B., Bianchi F.P., Falappone P.C.F., Spagnolo L., Gatti P. Coenzyme Q10&#x2009;+&#x2009;alpha lipoic acid for chronic COVID syndrome. Clin. Exp. Med. 2023;23:667&#x2013;678. doi: 10.1007/s10238-022-00871-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00871-8</ArticleId><ArticleId IdType="pmc">PMC9395797</ArticleId><ArticleId IdType="pubmed">35994177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Beckman K.B., Mehta T., Karger A.B., Odde D.J., Tignanelli C.J., Buse J.B., Johnson D.M., Watson R.H.B., Daniel J.J., et al. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin. Infect. Dis. 2024;79:354&#x2013;363. doi: 10.1093/cid/ciae159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae159</ArticleId><ArticleId IdType="pmc">PMC11327787</ArticleId><ArticleId IdType="pubmed">38690892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J.B., Liebovitz D.M., Nicklas J.M., Puskarich M.A., Cohen K., Belani H.K., Anderson B.J., Huling J.D., Tignanelli C.J., et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): A multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect. Dis. 2023;23:1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H., Tian L., Marconi V.C., Shafer R., McComsey G.A., Miglis M., Yang P., Bonilla A., Eggert L., Geng L.N. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int. Immunopharmacol. 2023;124:110966. doi: 10.1016/j.intimp.2023.110966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110966</ArticleId><ArticleId IdType="pmc">PMC11028858</ArticleId><ArticleId IdType="pubmed">37804660</ArticleId></ArticleIdList></Reference><Reference><Citation>Isman A., Nyquist A., Strecker B., Harinath G., Lee V., Zhang X., Zalzala S. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav. Immun. Health. 2024;36:100733. doi: 10.1016/j.bbih.2024.100733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2024.100733</ArticleId><ArticleId IdType="pmc">PMC10862402</ArticleId><ArticleId IdType="pubmed">38352659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamariz L., Bast E., Klimas N., Palacio A. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. Clin. Ther. 2024;46:e101&#x2013;e106. doi: 10.1016/j.clinthera.2023.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2023.12.009</ArticleId><ArticleId IdType="pubmed">38267326</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B., Vidal L., McHugh T., Woo J., Avramovic G., Lambert J.S. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav. Immun. Health. 2022;24:100485. doi: 10.1016/j.bbih.2022.100485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne A., Maskell S., Sharp C., Hamilton F.W., Arnold D.T. Impact of Dexamethasone on Persistent Symptoms of COVID-19: An Observational Study. Wellcome Open Res. 2023;8:145. doi: 10.12688/wellcomeopenres.18277.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.18277.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonet D.B., V&#xe9;lez O.A.C., Jord&#xe0; X.D., Serrano M.C., Rivera M.P., Admetll&#xf3; M., Blasco A.H., Godia E.C., Navarro E.M., Ezquerra G.M., et al. Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19. J. Clin. Med. 2023;12:4158. doi: 10.3390/jcm12124158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12124158</ArticleId><ArticleId IdType="pmc">PMC10299438</ArticleId><ArticleId IdType="pubmed">37373850</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogeweg M., Doevelaar A., Rieckmann S., Seibert F., Scholten D., Segelmacher M., Stervbo U., Babel N., Westhoff T.H. Intravenous immunoglobulins in the treatment of post-COVID: A case-control study. J. Intern. Med. 2023;293:656&#x2013;658. doi: 10.1111/joim.13592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13592</ArticleId><ArticleId IdType="pubmed">36414570</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson J.S., Thornton A.C., Ainger T., Garvy B.A. Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front. Immunol. 2022;13:1033651. doi: 10.3389/fimmu.2022.1033651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1033651</ArticleId><ArticleId IdType="pmc">PMC9932260</ArticleId><ArticleId IdType="pubmed">36818469</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Yogendra R., Guevara-Coto J., Mora-Rodriguez R.A., Osgood E., Bream J., Parikh P., Kreimer M., Jeffers D., Rutland C., et al. Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC) Front. Med. 2023;10:1122529. doi: 10.3389/fmed.2023.1122529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1122529</ArticleId><ArticleId IdType="pmc">PMC9944830</ArticleId><ArticleId IdType="pubmed">36844201</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi A., Ghodsi S., Memarjafari M., Nematollahi A., Sheikh-Sharbafan R., Sadre-Bafghi S.A., Moosavi S.V., Abdollahzadeh M., Jalali A., Farahani M.M. Long-Term Major Adverse Cardiovascular Events in Patients with Moderate and Severe COVID-19: A Focus on Early Statin Use and Previous CVD. J. Tehran Univ. Heart Cent. 2023;18:183&#x2013;195. doi: 10.18502/jthc.v18i3.14113.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/jthc.v18i3.14113</ArticleId><ArticleId IdType="pmc">PMC10748661</ArticleId><ArticleId IdType="pubmed">38146416</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T.H., Ho C.H., Chen D.T., Wu J.Y., Huang P.Y., Lai C.C., Hsieh K.Y., Su K.P. Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients. Brain Behav. Immun. 2023;114:453&#x2013;461. doi: 10.1016/j.bbi.2023.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.09.008</ArticleId><ArticleId IdType="pubmed">37716377</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R., Trimarco V., Mone P., Alo&#xe8; T., Marzani M.C., Diana A., Fazio G., Mallardo M., Maniscalco M., Marazzi G., et al. Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey. Pharmacol. Res. 2022;183:106360. doi: 10.1016/j.phrs.2022.106360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106360</ArticleId><ArticleId IdType="pmc">PMC9295384</ArticleId><ArticleId IdType="pubmed">35868478</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger B.R., Arron H.E., Booyens R.M., Kappert C., van Helden J., Weimer M., Weing&#xe4;rtner O., Seibel R., Reichl F., Khan A., et al. Long Covid Patients Successfully Treated by Means of Heparin-Mediated Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis. Infect. Dis. Diagn. Treat. 2023;7:216. doi: 10.29011/2577-1515.100216.</Citation><ArticleIdList><ArticleId IdType="doi">10.29011/2577-1515.100216</ArticleId></ArticleIdList></Reference><Reference><Citation>Achleitner M., Steenblock C., D&#xe4;nhardt J., Jarzebska N., Kardashi R., Kanczkowski W., Straube R., Rodionov R.N., Bornstein N., Tselmin S., et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol. Psychiatry. 2023;28:2872&#x2013;2877. doi: 10.1038/s41380-023-02084-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02084-1</ArticleId><ArticleId IdType="pmc">PMC10152027</ArticleId><ArticleId IdType="pubmed">37131073</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and Efficacy of Anakinra Treatment for Patients with Post Acute Covid Syndrome (PRECISION). ClinicalTrials.gov Identifier: NCT05926505.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05926505?cond=NCT05926505&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>Reclaim: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM). ClinicalTrials.gov Identifier: NCT05513560.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05513560?cond=NCT05513560&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>Solidarity Finland Plus Long-COVID. ClinicalTrials.gov Identifier: NCT05220280.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05220280.</Citation></Reference><Reference><Citation>Fluvoxamine for Long COVID-19. ClinicalTrials.gov Identifier: NCT05874037.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05874037?cond=NCT05874037&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>A Multicenter, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study in Participants with Long COVID-19: The REVIVE Trial (REVIVE). ClinicalTrials.gov Identifier: NCT06128967.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT06128967?cond=NCT06128967&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms. ClinicalTrials.gov Identifier: NCT05795816.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05795816?cond=NCT05795816&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>Immunerecov Contributes to Improvement of Respiratory and Immunological Response in Post-COVID-19 Patients. (IRPC). ClinicalTrials.gov Identifier: NCT06166030.  [(accessed on 20 September 2024)]; Available online:  https://clinicaltrials.gov/study/NCT06166030?cond=NCT06166030&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1.</Citation></Reference><Reference><Citation>Ortelli P., Quercia A., Cerasa A., Dezi S., Ferrazzoli D., Sebastianelli L., Saltuari L., Versace V., Quartarone A. Lowered Delta Activity in Post-COVID-19 Patients with Fatigue and Cognitive Impairment. Biomedicines. 2023;11:2228. doi: 10.3390/biomedicines11082228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11082228</ArticleId><ArticleId IdType="pmc">PMC10452696</ArticleId><ArticleId IdType="pubmed">37626724</ArticleId></ArticleIdList></Reference><Reference><Citation>Versace V., Sebastianelli L., Ferrazzoli D., Romanello R., Ortelli P., Saltuari L., D&#x2019;Acunto A., Porrazzini F., Ajello V., Oliviero A., et al. Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19. Clin. Neurophysiol. 2021;132:1138&#x2013;1143. doi: 10.1016/j.clinph.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7954785</ArticleId><ArticleId IdType="pubmed">33774378</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui K., Ozawa M., Kiso M., Yamashita M., Maekawa T., Kubota M., Sugano S., Kawaoka Y. Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Sci. Rep. 2018;8:4631. doi: 10.1038/s41598-018-22927-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22927-0</ArticleId><ArticleId IdType="pmc">PMC5854622</ArticleId><ArticleId IdType="pubmed">29545586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Puyo C.A. N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther. Clin. Risk Manag. 2020;16:1047&#x2013;1055. doi: 10.2147/TCRM.S273700.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S273700</ArticleId><ArticleId IdType="pmc">PMC7649937</ArticleId><ArticleId IdType="pubmed">33177829</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger J., Parkitny L., McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin. Rheumatol. 2014;33:451&#x2013;459. doi: 10.1007/s10067-014-2517-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2517-2</ArticleId><ArticleId IdType="pmc">PMC3962576</ArticleId><ArticleId IdType="pubmed">24526250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sifuentes-Franco S., S&#xe1;nchez-Mac&#xed;as D.C., Carrillo-Ibarra S., Rivera-Vald&#xe9;s J.J., Zu&#xf1;iga L.Y., S&#xe1;nchez-L&#xf3;pez V.A. Antioxidant and Anti-Inflammatory Effects of Coenzyme Q10 Supplementation on Infectious Diseases. Healthcare. 2022;10:487. doi: 10.3390/healthcare10030487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10030487</ArticleId><ArticleId IdType="pmc">PMC8953254</ArticleId><ArticleId IdType="pubmed">35326965</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Liu X., Bai T., Fan H., Hong K., Song H., Han Y., Lin L., Ruan L., Li T. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect. Dis. 2020;7:ofaa102. doi: 10.1093/ofid/ofaa102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa102</ArticleId><ArticleId IdType="pmc">PMC7111600</ArticleId><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinkmann G., Altrichter J., Reuter D.A., Mitzner S. Therapeutic apheresis in sepsis. Ther. Apher. Dial. 2022;26:64&#x2013;72. doi: 10.1111/1744-9987.13815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1744-9987.13815</ArticleId><ArticleId IdType="pubmed">36468315</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher A., Tintle N.L., Myers M., Lockshon L., Bacareza H., Harris W.S. Blood omega-3 fatty acids and death from COVID-19: A pilot study. Prostaglandins Leukot. Essent. Fat. Acids. 2021;166:102250. doi: 10.1016/j.plefa.2021.102250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2021.102250</ArticleId><ArticleId IdType="pmc">PMC7816864</ArticleId><ArticleId IdType="pubmed">33516093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.S., Noh J.Y., Song J.Y., Cheong H.J., Kim W.J. Metformin reduces the risk of developing influenza A virus related cardiovascular disease. Heliyon. 2023;9:e20284. doi: 10.1016/j.heliyon.2023.e20284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20284</ArticleId><ArticleId IdType="pmc">PMC10556598</ArticleId><ArticleId IdType="pubmed">37810823</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarco V., Izzo R., Lombardi A., Coppola A., Fiorentino G., Santulli G. Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial. Pharmacol. Res. 2023;191:106702. doi: 10.1016/j.phrs.2023.106702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2023.106702</ArticleId><ArticleId IdType="pmc">PMC9928676</ArticleId><ArticleId IdType="pubmed">36804278</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels L.B., Sitapati A.M., Zhang J., Zou J., Bui Q.M., Ren J., Longhurst C.A., Criqui M.H., Messer K. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am. J. Cardiol. 2020;136:149&#x2013;155. doi: 10.1016/j.amjcard.2020.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.09.012</ArticleId><ArticleId IdType="pmc">PMC7492151</ArticleId><ArticleId IdType="pubmed">32946859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.J., Qin J.J., Cheng X., Shen L., Zhao Y.C., Yuan Y., Lei F., Chen M.M., Yang H., Bai L., et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32:176&#x2013;187.e4. doi: 10.1016/j.cmet.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7311917</ArticleId><ArticleId IdType="pubmed">32592657</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinosoglou K., Kotsaki A., Gounaridi I.M., Christaki E., Metallidis S., Adamis G., Fragkou A., Fantoni M., Rapti A., Kalomenidis I., et al. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial. EClinicalMedicine. 2023;56:101785. doi: 10.1016/j.eclinm.2022.101785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101785</ArticleId><ArticleId IdType="pmc">PMC9791950</ArticleId><ArticleId IdType="pubmed">36590789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Panagopoulos P., Metallidis S., Dalekos G.N., Poulakou G., Gatselis N., Karakike E., Saridaki M., Loli G., Stefos A., et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021;10:e66125. doi: 10.7554/eLife.66125.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.66125</ArticleId><ArticleId IdType="pmc">PMC8034977</ArticleId><ArticleId IdType="pubmed">33682678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Poulakou G., Milionis H., Metallidis S., Adamis G., Tsiakos K., Fragkou A., Rapti A., Damoulari C., Fantoni M., et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat. Med. 2021;27:1752&#x2013;1760. doi: 10.1038/s41591-021-01499-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01499-z</ArticleId><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>Huet T., Beaussier H., Voisin O., Jouveshomme S., Dauriat G., Lazareth I., Sacco E., Naccache J.M., B&#xe9;zie Y., Laplanche S., et al. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol. 2020;2:e393&#x2013;e400. doi: 10.1016/S2665-9913(20)30164-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30164-8</ArticleId><ArticleId IdType="pmc">PMC7259909</ArticleId><ArticleId IdType="pubmed">32835245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov. Ment. Health. 2023;3:9. doi: 10.1007/s44192-023-00036-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44192-023-00036-3</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiakalos A., Ziakas P.D., Polyzou E., Schinas G., Akinosoglou K. Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis. Microorganisms. 2023;11:2073. doi: 10.3390/microorganisms11082073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082073</ArticleId><ArticleId IdType="pmc">PMC10459506</ArticleId><ArticleId IdType="pubmed">37630633</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Dos Santos Moreira-Silva E.A., Silva D.C.M., Thabane L., Milagres A.C., Ferreira T.S., Dos Santos C.V.Q., de Souza Campos V.H., Nogueira A.M.R., de Almeida A., et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob. Health. 2022;10:e42&#x2013;e51. doi: 10.1016/S2214-109X(21)00448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanchlani N., Lin S., Chee D., Hamilton B., Nice R., Arkir Z., Bewshea C., Cipriano B., Derikx L., Dunlop A., et al. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J. Crohn&#x2019;s Colitis. 2022;16:389&#x2013;397. doi: 10.1093/ecco-jcc/jjab153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab153</ArticleId><ArticleId IdType="pmc">PMC8499950</ArticleId><ArticleId IdType="pubmed">34473254</ArticleId></ArticleIdList></Reference><Reference><Citation>Amodeo A., Persani L., Bonomi M., Cangiano B. Use of testosterone replacement therapy to treat long-COVID-related hypogonadism. Endocrinol. Diabetes Metab. Case Rep. 2024;2024:230097. doi: 10.1530/EDM-23-0097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EDM-23-0097</ArticleId><ArticleId IdType="pmc">PMC10959025</ArticleId><ArticleId IdType="pubmed">38520748</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan N.M., Warda A.E.A., Ibrahim H.S.G., Schaalan M.F., Fathy S.M. Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. Sci. Rep. 2023;13:6456. doi: 10.1038/s41598-023-33484-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-33484-6</ArticleId><ArticleId IdType="pmc">PMC10116445</ArticleId><ArticleId IdType="pubmed">37081046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin A., Shabsigh R., Al-Zoubi R.M., Aboumarzouk O.M., Alwani M., Nettleship J., Kelly D. Testosterone and Covid-19: An update. Rev. Med. Virol. 2023;33:e2395. doi: 10.1002/rmv.2395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2395</ArticleId><ArticleId IdType="pmc">PMC9537909</ArticleId><ArticleId IdType="pubmed">36056748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa-Hedeab G., Al-Kuraishy H.M., Al-Gareeb A.I., Jeandet P., Saad H.M., Batiha G.E. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology. 2022;30:799&#x2013;809. doi: 10.1007/s10787-022-00993-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00993-1</ArticleId><ArticleId IdType="pmc">PMC9051499</ArticleId><ArticleId IdType="pubmed">35486310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan R.M., Altyar A.E., Essam Abou Warda A., Saied Y.M., Ibrahim H.S.G., Schaalan M.F., Fathy S., Sarhan N., Boshra M.S. Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial. Pharmaceuticals. 2023;16:631. doi: 10.3390/ph16040631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040631</ArticleId><ArticleId IdType="pmc">PMC10142327</ArticleId><ArticleId IdType="pubmed">37111389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus-Silva J.R., Oliveira C.R., Brandao-Rangel M.A.R., Silva-Reis A., Olimpio F., Zamarioli L.D.S., Aimbire F., Vieira R.P. A Nutritional Blend Suppresses the Inflammatory Response from Bronchial Epithelial Cells Induced by SARS-CoV-2. J. Diet. Suppl. 2023;20:156&#x2013;170. doi: 10.1080/19390211.2022.2103607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2022.2103607</ArticleId><ArticleId IdType="pubmed">35930300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomaa A.A., Abdel-Wadood Y.A., Thabet R.H., Gomaa G.A. Pharmacological evaluation of vitamin D in COVID-19 and long COVID-19: Recent studies confirm clinical validation and highlight metformin to improve VDR sensitivity and efficacy. Inflammopharmacology. 2024;32:249&#x2013;271. doi: 10.1007/s10787-023-01383-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01383-x</ArticleId><ArticleId IdType="pmc">PMC10907442</ArticleId><ArticleId IdType="pubmed">37957515</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi M.K. What is the future for covid drugs and treatments? BMJ. 2023;381:1001. doi: 10.1136/bmj.p1001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p1001</ArticleId><ArticleId IdType="pubmed">37164386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.K., Ng Y.L., Ahidjo B.A., Aw Z.Q., Chen H., Wong Y.H., Lee R.C.H., Loe M.W.C., Liu J., Tan K.S., et al. Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants. Pharmaceutics. 2023;15:925. doi: 10.3390/pharmaceutics15030925.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15030925</ArticleId><ArticleId IdType="pmc">PMC10058714</ArticleId><ArticleId IdType="pubmed">36986786</ArticleId></ArticleIdList></Reference><Reference><Citation>Stapleton E.M., Keck K., Windisch R., Stroik M.R., Thurman A.L., Zabner J., Thornell I.M., Pezzulo A.A., Klesney-Tait J., Comellas A.P. Vitamin D-mediated effects on airway innate immunity in vitro. PLoS ONE. 2022;17:e0269647. doi: 10.1371/journal.pone.0269647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269647</ArticleId><ArticleId IdType="pmc">PMC9170100</ArticleId><ArticleId IdType="pubmed">35666753</ArticleId></ArticleIdList></Reference><Reference><Citation>Topan A., Lupse M., Calin M., Jianu C., Leucuta D.C., Briciu V. 25 Hydroxyvitamin D Serum Concentration and COVID-19 Severity and Outcome-A Retrospective Survey in a Romanian Hospital. Nutrients. 2023;15:1227. doi: 10.3390/nu15051227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15051227</ArticleId><ArticleId IdType="pmc">PMC10005256</ArticleId><ArticleId IdType="pubmed">36904227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Sandoval J.C., Castillos-&#xc1;valos V.J., Paz-Cort&#xe9;s A., Santillan-Ceron A., Hernandez-Jimenez S., Mehta R., Correa-Rotter R. Very Low Vitamin D Levels are a Strong Independent Predictor of Mortality in Hospitalized Patients with Severe COVID-19. Arch. Med. Res. 2022;53:215&#x2013;222. doi: 10.1016/j.arcmed.2021.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.09.006</ArticleId><ArticleId IdType="pmc">PMC8516726</ArticleId><ArticleId IdType="pubmed">34711432</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L., Uygur M., Locatelli M., Nannipieri F., Frara S., Giustina A. Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization. Endocrine. 2023;80:669&#x2013;683. doi: 10.1007/s12020-023-03331-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-023-03331-9</ArticleId><ArticleId IdType="pmc">PMC9974397</ArticleId><ArticleId IdType="pubmed">36854858</ArticleId></ArticleIdList></Reference><Reference><Citation>Argano C., Mallaci Bocchio R., Natoli G., Scibetta S., Lo Monaco M., Corrao S. Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. Pharmaceuticals. 2023;16:130. doi: 10.3390/ph16010130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16010130</ArticleId><ArticleId IdType="pmc">PMC9864223</ArticleId><ArticleId IdType="pubmed">36678627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero A.F.G., Fogacci F., Borghi C. Vitamin D Supplementation and COVID-19 Outcomes: Mounting Evidence and Fewer Doubts. Nutrients. 2022;14:3584. doi: 10.3390/nu14173584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14173584</ArticleId><ArticleId IdType="pmc">PMC9460517</ArticleId><ArticleId IdType="pubmed">36079842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Brown G.M., Pandi-Perumal S.R. Possible Application of Melatonin in Long COVID. Biomolecules. 2022;12:1646. doi: 10.3390/biom12111646.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12111646</ArticleId><ArticleId IdType="pmc">PMC9687267</ArticleId><ArticleId IdType="pubmed">36358996</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;-A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Acu&#xf1;a-Castroviejo D., Escames G., Figueira J.C., de la Oliva P., Borobia A.M., Acu&#xf1;a-Fern&#xe1;ndez C. Clinical trial to test the efficacy of melatonin in COVID-19. J. Pineal Res. 2020;69:e12683. doi: 10.1111/jpi.12683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12683</ArticleId><ArticleId IdType="pmc">PMC7435535</ArticleId><ArticleId IdType="pubmed">32770854</ArticleId></ArticleIdList></Reference><Reference><Citation>Artigas L., Coma M., Matos-Filipe P., Aguirre-Plans J., Farr&#xe9;s J., Valls R., Fernandez-Fuentes N., de la Haba-Rodriguez J., Olvera A., Barbera J., et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE. 2020;15:e0240149. doi: 10.1371/journal.pone.0240149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240149</ArticleId><ArticleId IdType="pmc">PMC7531795</ArticleId><ArticleId IdType="pubmed">33006999</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Sharma R., Ma Q., Dominquez-Rodriguez A., Marik P.E., Abreu-Gonzalez P. Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis. Med. Drug Discov. 2020;6:100044. doi: 10.1016/j.medidd.2020.100044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2020.100044</ArticleId><ArticleId IdType="pmc">PMC7211589</ArticleId><ArticleId IdType="pubmed">32395713</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds J.L., Dubocovich M.L. Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19. J. Pineal Res. 2021;71:e12732. doi: 10.1111/jpi.12732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12732</ArticleId><ArticleId IdType="pmc">PMC8250125</ArticleId><ArticleId IdType="pubmed">33759236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H., Karri V., Tay N.W.R., Chang K.H., Ah H.Y., Ng P.Q., Ho H.S., Keh H.W., Candasamy M. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease. Biomed. Pharmacother. 2019;111:765&#x2013;777. doi: 10.1016/j.biopha.2018.12.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.12.101</ArticleId><ArticleId IdType="pubmed">30612001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumsuzzman D.M., Choi J., Jin Y., Hong Y. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer&#x2019;s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. Neurosci. Biobehav. Rev. 2021;127:459&#x2013;473. doi: 10.1016/j.neubiorev.2021.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.04.034</ArticleId><ArticleId IdType="pubmed">33957167</ArticleId></ArticleIdList></Reference><Reference><Citation>Habtemariam S., Daglia M., Sureda A., Selamoglu Z., Gulhan M.F., Nabavi S.M. Melatonin and Respiratory Diseases: A Review. Curr. Top. Med. Chem. 2017;17:467&#x2013;488. doi: 10.2174/1568026616666160824120338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160824120338</ArticleId><ArticleId IdType="pubmed">27558675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeland R. Melatonin and inflammation-Story of a double-edged blade. J. Pineal Res. 2018;65:e12525. doi: 10.1111/jpi.12525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12525</ArticleId><ArticleId IdType="pubmed">30242884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>